Cytokinetics is following in the footsteps of Bristol Myers Squibb as it prepares to try to wrest control of a heart disease ...

The clock is up on Biogen’s extra two years of a biosimilar-free U.S. market for its blockbuster multiple sclerosis (MS) med ...

Despite many overseas drugmakers gaining some tariff clarity when the U.S. | Thanks to a new accord with the United States, ...

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

Nearly three years after striking up a Zymeworks licensing pact with an eye on challenging the status quo in HER2-positive ...

In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...

The updated label now includes a boxed warning and a new “limitation of use" in addition to the removal of the prior ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

Just as the dust had settled around Pfizer’s brief Metsera bidding war with Novo Nordisk, another planned biopharma ...

Shortly after crossing the FDA’s finish line, Ionis Pharmaceuticals’ RNA-targeted hereditary angioedema (HAE) treatment ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies ...